AU2208097A - Muscular dystrophy, stroke, and neurodegenerative disease diagnosis and treatment - Google Patents

Muscular dystrophy, stroke, and neurodegenerative disease diagnosis and treatment

Info

Publication number
AU2208097A
AU2208097A AU22080/97A AU2208097A AU2208097A AU 2208097 A AU2208097 A AU 2208097A AU 22080/97 A AU22080/97 A AU 22080/97A AU 2208097 A AU2208097 A AU 2208097A AU 2208097 A AU2208097 A AU 2208097A
Authority
AU
Australia
Prior art keywords
stroke
treatment
neurodegenerative disease
muscular dystrophy
disease diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22080/97A
Inventor
David S. Bredt
Jay E. BRENMAN
Daniel S. Chao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU2208097A publication Critical patent/AU2208097A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2878—Muscular dystrophy
AU22080/97A 1996-03-08 1997-03-06 Muscular dystrophy, stroke, and neurodegenerative disease diagnosis and treatment Abandoned AU2208097A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61311496A 1996-03-08 1996-03-08
US08613114 1996-03-08
PCT/US1997/003897 WO1997033173A1 (en) 1996-03-08 1997-03-06 Muscular dystrophy, stroke, and neurodegenerative disease diagnosis and treatment

Publications (1)

Publication Number Publication Date
AU2208097A true AU2208097A (en) 1997-09-22

Family

ID=24455919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22080/97A Abandoned AU2208097A (en) 1996-03-08 1997-03-06 Muscular dystrophy, stroke, and neurodegenerative disease diagnosis and treatment

Country Status (2)

Country Link
AU (1) AU2208097A (en)
WO (1) WO1997033173A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225444B1 (en) * 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
CA2371927A1 (en) * 1999-03-11 2000-09-14 The University Of Manitoba Nitric oxide manipulation of muscle satellite cell activation
US6967102B1 (en) 1999-03-11 2005-11-22 University Of Manitoba Nitric oxide manipulation of muscle satellite cell activation
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
FR2794647A1 (en) 1999-06-11 2000-12-15 Centre Nat Rech Scient PHARMACEUTICAL COMPOSITIONS COMPRISING NO OR AT LEAST A COMPOUND CAPABLE OF RELEASING OR INDUCING THE FORMATION OF NO IN CELLS
GB0008321D0 (en) * 2000-04-06 2000-05-24 Univ Court Of The University O Biological material and uses thereof
US6428967B1 (en) 2000-05-01 2002-08-06 Board Of Regents, The University Of Texas System LDL receptor signaling pathways
US20020045590A1 (en) 2000-10-23 2002-04-18 Yuanxiang Tao Inhibition of interaction of PSD93 and PSD95 with nNOS and NMDA receptors
WO2001087285A2 (en) * 2000-05-12 2001-11-22 The Johns Hopkins University Inhibition of the interaction of psd93 and psd95 with the nnos and nmda receptors
US20060252677A1 (en) * 2001-11-20 2006-11-09 Osamu Ohara Postsynaptic proteins
GB0907516D0 (en) * 2009-04-30 2009-06-10 Univ Birmingham Assay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7312891A (en) * 1990-02-12 1991-09-03 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
US5260209A (en) * 1990-05-23 1993-11-09 University Of Iowa Research Foundation Nucleic acids encoding dystrophin-associated proteins
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity

Also Published As

Publication number Publication date
WO1997033173A1 (en) 1997-09-12

Similar Documents

Publication Publication Date Title
EP0710667B8 (en) Modified oligonucleotides, their preparation and their use
EP0668052A3 (en) Ultrasonic diagnosis and treatment system.
AUPP784398A0 (en) Kidney disease detection and treatment
NZ292980A (en) Smooth, spherical water-soluble microparticles as therapeutic or diagnostic vehicles
AU679663B2 (en) Dermatological or pharmaceutical composition, preparation process and use
AU5772196A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU3378297A (en) Blood treatment system
HUP9602745A3 (en) Anticelladhesive piperidine- und pyrrolidine-carbonacids, pharm
ZA977313B (en) Medical tube assemblies.
ZA964710B (en) Novel compounds, the preparation and use thereof.
ZA975593B (en) Medical device.
AU5772296A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772396A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU6246199A (en) Human interleukin-b50, therapeutic uses
AU2208097A (en) Muscular dystrophy, stroke, and neurodegenerative disease diagnosis and treatment
AU7624598A (en) 1,4-diazabicyclo (2.2.2) Oct-2-ylmethyl derivatives, their preparation and the rapeutic application
ZA9610278B (en) Pyridylcarbamates, processes and intermediates for their preparation, and their use.
AU1138699A (en) Dna demethylase, therapeutic and diagnostic uses thereof
ZA964821B (en) Bone stimulating factor.
AU2768995A (en) Human elastase iv
AU6774198A (en) Human rab protein, srab
GB9606076D0 (en) Diabetes treatment
ZA957020B (en) Breath malodour reduction.
GB9521725D0 (en) Medical treatment
ZA966661B (en) Catalyst, use thereof and preparation process.